Literature DB >> 23111472

Assessment of renal function after conformal radiotherapy and intensity-modulated radiotherapy by functional 1H-MRI and 23Na-MRI.

S Haneder1, H J Michaely, S O Schoenberg, S Konstandin, L R Schad, K Siebenlist, H Wertz, F Wenz, F Lohr, J Boda-Heggemann.   

Abstract

PURPOSE: Adjuvant radiochemotherapy (RCHT) improves survival of patients with locally advanced gastric cancer. Conventional three-dimensional conformal radiotherapy (3D-CRT) results in ablative doses to a significant amount of the left kidney, while image-guided intensity-modulated radiotherapy (IG-IMRT) provides excellent target coverage with improved kidney sparing. Few long-term results on IMRT for gastric cancer, however, have been published. Functional magnetic resonance imaging (fMRI) at 3.0 T including blood oxygenation-level dependent (BOLD) imaging, diffusion-weighted imaging (DWI) and, for the first time, (23)Na imaging was used to evaluate renal status after radiotherapy with 3D-CRT or IG-IMRT. PATIENTS AND METHODS: Four disease-free patients (2 after 3D-CRT and 2 after IMRT; FU for all patients > 5 years) were included in this feasibility study. Morphological sequences, axial DWI images, 2D-gradient echo (GRE)-BOLD images, and (23)Na images were acquired. Mean values/standard deviations for ((23)Na), the apparent diffusion coefficient (ADC), and R2* values were calculated for the upper/middle/lower parts of both kidneys. Corticomedullary (23)Na-concentration gradients were determined.
RESULTS: Surprisingly, IG-IMRT patients showed no morphological alterations and no statistically significant differences of ADC and R2* values in all renal parts. Values for mean corticomedullary (23)Na-concentration matched those for healthy volunteers. Results were similar in 3D-CRT patients, except for the cranial part of the left kidney. This was atrophic and presented significantly reduced functional parameters (p = 0.001-p = 0.033). Reduced ADC values indicated reduced cell density and reduced extracellular space. Cortical and medullary R2* values of the left cranial kidney in the 3D-CRT group were higher, indicating more deoxygenated hemoglobin due to reduced blood flow/oxygenation. ((23)Na) of the renal cranial parts in the 3D-CRT group was significantly reduced, while the expected corticomedullary (23)Na-concentration gradient was partially conserved.
CONCLUSIONS: Functional MRI can assess postradiotherapeutic renal changes. As expected, marked morphological/functional effects were observed in high-dose areas (3D-CRT), while, unexpectedly, no alteration in kidney function was observed in IG-IMRT patients, supporting the hypothesis that reducing total/fractional dose to the renal parenchyma by IMRT is clinically beneficial.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23111472     DOI: 10.1007/s00066-012-0254-5

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  25 in total

1.  Toxicity after intensity-modulated, image-guided radiotherapy for prostate cancer.

Authors:  Matthias Guckenberger; Sami Ok; Bülent Polat; Reinhart A Sweeney; Michael Flentje
Journal:  Strahlenther Onkol       Date:  2010-09-30       Impact factor: 3.621

2.  Functional evaluation of transplanted kidneys with diffusion-weighted and BOLD MR imaging: initial experience.

Authors:  Harriet C Thoeny; Dominik Zumstein; Sonja Simon-Zoula; Ute Eisenberger; Frederik De Keyzer; Lucie Hofmann; Peter Vock; Chris Boesch; Felix J Frey; Peter Vermathen
Journal:  Radiology       Date:  2006-12       Impact factor: 11.105

Review 3.  Functional renal imaging: nonvascular renal disease.

Authors:  H J Michaely; K A Herrmann; K Nael; N Oesingmann; M F Reiser; S O Schoenberg
Journal:  Abdom Imaging       Date:  2006-01-30

4.  Sodium MRI using a density-adapted 3D radial acquisition technique.

Authors:  Armin M Nagel; Frederik B Laun; Marc-André Weber; Christian Matthies; Wolfhard Semmler; Lothar R Schad
Journal:  Magn Reson Med       Date:  2009-12       Impact factor: 4.668

5.  Changes in renal medullary pO2 during water diuresis as evaluated by blood oxygenation level-dependent magnetic resonance imaging: effects of aging and cyclooxygenase inhibition.

Authors:  P V Prasad; F H Epstein
Journal:  Kidney Int       Date:  1999-01       Impact factor: 10.612

6.  Volumetric modulated arc therapy for advanced pancreatic cancer.

Authors:  Wietse Eppinga; Frank Lagerwaard; Wilko Verbakel; Ben Slotman; Suresh Senan
Journal:  Strahlenther Onkol       Date:  2010-06-24       Impact factor: 3.621

7.  Adenocarcinoma of the esophagogastric junction: neoadjuvant radiochemotherapy and radical surgery : early results and toxicity.

Authors:  Bernhard J Leibl; Stephanie Vitz; Wolfgang Schäfer; Martin Alfrink; Andreas Gschwendtner; Gerhard G Grabenbauer
Journal:  Strahlenther Onkol       Date:  2011-03-24       Impact factor: 3.621

8.  Optimization of dose distributions for adjuvant locoregional radiotherapy of gastric cancer by IMRT.

Authors:  Frank Lohr; Barbara Dobler; Sabine Mai; Brigitte Hermann; Uta Tiefenbacher; Petra Wieland; Volker Steil; Frederik Wenz
Journal:  Strahlenther Onkol       Date:  2003-08       Impact factor: 3.621

9.  Accuracy of ultrasound-based image guidance for daily positioning of the upper abdomen: an online comparison with cone beam CT.

Authors:  Judit Boda-Heggemann; Philipp Mennemeyer; Hansjörg Wertz; Nadja Riesenacker; Beate Küpper; Frank Lohr; Frederik Wenz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-04-23       Impact factor: 7.038

10.  Detection of evolving acute tubular necrosis with renal 23Na MRI: studies in rats.

Authors:  N Maril; R Margalit; S Rosen; S N Heyman; H Degani
Journal:  Kidney Int       Date:  2006-02       Impact factor: 10.612

View more
  8 in total

Review 1.  Current MRI techniques for the assessment of renal disease.

Authors:  Takamune Takahashi; Feng Wang; Christopher C Quarles
Journal:  Curr Opin Nephrol Hypertens       Date:  2015-05       Impact factor: 2.894

2.  Quantitative in vivo 23Na MR imaging of the healthy human kidney: determination of physiological ranges at 3.0T with comparison to DWI and BOLD.

Authors:  Stefan Haneder; Paul Kettnaker; Simon Konstandin; John N Morelli; Lothar R Schad; Stefan O Schoenberg; Henrik J Michaely
Journal:  MAGMA       Date:  2013-03-09       Impact factor: 2.310

3.  Dose-dependent changes in renal (1)H-/(23)Na MRI after adjuvant radiochemotherapy for gastric cancer.

Authors:  Stefan Haneder; Johannes Michael Budjan; Stefan Oswald Schoenberg; Simon Konstandin; Lothar Rudi Schad; Ralf Dieter Hofheinz; Veronika Gramlich; Frederik Wenz; Frank Lohr; Judit Boda-Heggemann
Journal:  Strahlenther Onkol       Date:  2014-12-02       Impact factor: 3.621

4.  Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer.

Authors:  J Boda-Heggemann; C Weiss; V Schneider; R-D Hofheinz; S Haneder; H Michaely; H Wertz; U Ronellenfitsch; A Hochhaus; F Wenz; F Lohr
Journal:  Strahlenther Onkol       Date:  2013-04-06       Impact factor: 3.621

5.  3T renal (23)Na-MRI: effects of desmopressin in patients with central diabetes insipidus.

Authors:  Stefan Haneder; Henrik J Michaely; Simon Konstandin; Lothar R Schad; John N Morelli; Bernhard K Krämer; Stefan O Schoenberg; Alexander Lammert
Journal:  MAGMA       Date:  2013-04-06       Impact factor: 2.310

6.  Automated VMAT planning for postoperative adjuvant treatment of advanced gastric cancer.

Authors:  Abdul Wahab M Sharfo; Florian Stieler; Oskar Kupfer; Ben J M Heijmen; Maarten L P Dirkx; Sebastiaan Breedveld; Frederik Wenz; Frank Lohr; Judit Boda-Heggemann; Daniel Buergy
Journal:  Radiat Oncol       Date:  2018-04-23       Impact factor: 3.481

Review 7.  Recent advances in renal imaging.

Authors:  Joshua Thurman; Faikah Gueler
Journal:  F1000Res       Date:  2018-11-29

Review 8.  Radiotherapy for tumors of the stomach and gastroesophageal junction--a review of its role in multimodal therapy.

Authors:  Daniel Buergy; Frank Lohr; Tobias Baack; Kerstin Siebenlist; Stefan Haneder; Henrik Michaely; Frederik Wenz; Judit Boda-Heggemann
Journal:  Radiat Oncol       Date:  2012-11-16       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.